Sunday, 24 June 2018
Latest news
Main » Johnson & Johnson says pricing competition squeezing sales

Johnson & Johnson says pricing competition squeezing sales

19 April 2017
Johnson & Johnson says pricing competition squeezing sales

Landmark Financial Advisors LLC increased its stake in shares of Johnson & Johnson by 0.5% in the fourth quarter.

Modest growth across the board led to the company's largely flat operational growth of 1% year over year, excluding acquisition and divestitures. Keystone Financial Planning Inc. raised its stake in shares of Johnson & Johnson by 0.3% in the third quarter.

J&J expects adjusted earnings per share in the range of $7.00 - $7.15 for 2017 compared with $6.93 to $7.08 expected previously. Finally, Valicenti Advisory Services Inc. increased its stake in shares of Johnson & Johnson by 0.7% in the third quarter. Stock traders acquired 3,039 put options on the company.

As the earnings date approaches, we can see that insider ownership is now 0.02% shares, and institutional ownership is at 67.40% for Johnson & Johnson (NYSE:JNJ) stock. Following the completion of the transaction, the vice president now directly owns 127,650 shares in the company, valued at approximately $14,972,068.50. Intact Investment Management Inc.'s holdings in Johnson & Johnson were worth $18,070,000 at the end of the most recent quarter.

Shares of Johnson & Johnson (NYSE:JNJ) opened at 124.99 on Friday. The stock now shows its YTD (Year to Date) performance of 9.84 percent while its Weekly performance value is 0.64%.

The stock increased 0.58% or $0.73 during the last trading session, hitting $125.77. The stock is now trading with a distance of 20-Day Simple Moving Average (SMA20) of 0.19%.

Johnson & Johnson (NYSE:JNJ)'s earnings is on the doorstep as the firm is set to report on 4/18/2017 8:30:00 AM. The current consensus recommendation provided by covering analysts is 2.50.

Sales came in at $17.77 billion, missing the Zacks Consensus Estimate of $18.0 billion by 1.3%. The Return on Investment (ROI) is at 17% while it's Return on Equity (ROE) value stands at 22.9%. The company's quarterly revenue was up 1.7% on a year-over-year basis. The company's quarterly revenue was up 1.6% on a year-over-year basis.

The Band-Aid maker got off to a rocky start this year, forecasting in January sales and profit for 2017 below Street estimates, and said it expected a slower growth rate for pharmaceuticals in the year.

Argus Research Upgrades Johnson & Johnson (JNJ) to Buy with a price target of $145. Johnson & Johnson has a 12-month low of $109.32 and a 12-month high of $129.00. Jefferies Maintains the company's stock to Hold on 8/04/16 by setting a price target of $119. Two investment analysts have rated the stock with a sell rating, twelve have assigned a hold rating and six have issued a buy rating to the company's stock. Finally, Royal Bank of Canada reduced their target price on shares of Johnson & Johnson from $133.00 to $128.00 and set an "outperform" rating on the stock in a research note on Wednesday, January 25th.

J&J in February agreed to sell its Codman neurosurgery business for more than $1 billion. The shares were sold at an average price of $117.29, for a total transaction of $2,580,380.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Over the past few months, insider ownership has seen a move of -20.22% while institutional ownership has changed -0.11%.